纳米载体系统协同递送siRNA和化疗药物用于乳腺癌治疗的最新进展。

IF 1.9 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2025-09-18 DOI:10.1080/07357907.2025.2559088

Neha Laxane, Khushwant S Yadav

{"title":"纳米载体系统协同递送siRNA和化疗药物用于乳腺癌治疗的最新进展。","authors":"Neha Laxane, Khushwant S Yadav","doi":"10.1080/07357907.2025.2559088","DOIUrl":null,"url":null,"abstract":"Breast cancer's heterogeneity demands innovative therapies. Co-delivery of therapeutics using nanocarriers, especially siRNA combined with other chemotherapeutic drugs, presents a promising avenue. These systems safeguard siRNA, enhance its cellular uptake, and facilitate simultaneous targeting of multiple oncogenic pathways. This multifaceted approach holds potential for superior efficacy and reduced toxicity, addressing the limitations of conventional treatments and paving the way for improved breast cancer therapy.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1-20"},"PeriodicalIF":1.9000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recent Advances in Nanocarrier Systems for the Co-Delivery of siRNA and Chemotherapeutic Drug for Breast Cancer Therapy.\",\"authors\":\"Neha Laxane, Khushwant S Yadav\",\"doi\":\"10.1080/07357907.2025.2559088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Breast cancer's heterogeneity demands innovative therapies. Co-delivery of therapeutics using nanocarriers, especially siRNA combined with other chemotherapeutic drugs, presents a promising avenue. These systems safeguard siRNA, enhance its cellular uptake, and facilitate simultaneous targeting of multiple oncogenic pathways. This multifaceted approach holds potential for superior efficacy and reduced toxicity, addressing the limitations of conventional treatments and paving the way for improved breast cancer therapy.\",\"PeriodicalId\":9463,\"journal\":{\"name\":\"Cancer Investigation\",\"volume\":\" \",\"pages\":\"1-20\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/07357907.2025.2559088\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2025.2559088","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

乳腺癌的异质性要求创新疗法。使用纳米载体，特别是siRNA与其他化疗药物联合使用，是一种很有前途的治疗方法。这些系统保护siRNA，增强其细胞摄取，并促进同时靶向多种致癌途径。这种多方面的方法具有更高的疗效和降低毒性的潜力，解决了传统治疗的局限性，并为改进乳腺癌治疗铺平了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Recent Advances in Nanocarrier Systems for the Co-Delivery of siRNA and Chemotherapeutic Drug for Breast Cancer Therapy.

Breast cancer's heterogeneity demands innovative therapies. Co-delivery of therapeutics using nanocarriers, especially siRNA combined with other chemotherapeutic drugs, presents a promising avenue. These systems safeguard siRNA, enhance its cellular uptake, and facilitate simultaneous targeting of multiple oncogenic pathways. This multifaceted approach holds potential for superior efficacy and reduced toxicity, addressing the limitations of conventional treatments and paving the way for improved breast cancer therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.